0001209191-23-056008.txt : 20231120 0001209191-23-056008.hdr.sgml : 20231120 20231120152844 ACCESSION NUMBER: 0001209191-23-056008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231117 FILED AS OF DATE: 20231120 DATE AS OF CHANGE: 20231120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MIDDLETON FRED A CENTRAL INDEX KEY: 0001267959 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35867 FILM NUMBER: 231422536 MAIL ADDRESS: STREET 1: 400 SOUTH EL CAMINO REAL STE 1200 CITY: SAN MATEO STATE: CA ZIP: 94402-1708 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHIMERIX INC CENTRAL INDEX KEY: 0001117480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330903395 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919.806.1074 MAIL ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-11-17 0 0001117480 CHIMERIX INC CMRX 0001267959 MIDDLETON FRED A C/O CHIMERIX, INC. 2505 MERIDIAN PARKWAY, SUITE 100 DURHAM NC 27713 1 0 0 0 0 Common Stock 2023-11-17 4 P 0 17295 0.9553 A 100000 I Fred A. Middleton Separate Property Trust Common Stock 207523 D Common Stock 2776093 I See footnote Common Stock 531861 I See footnote The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9500 to $0.9600, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. The securities are held as follows: 829,046 shares of common stock held by Sanderling Venture Partners V, L.P., 233,134 shares of common stock held by Sanderling V Biomedical, L.P., 155,143 shares of common stock held by Sanderling V Limited Partnership, 138,046 shares of common stock held by Sanderling V Beteiligungs GmbH & Co. KG, 199,853 shares of common stock held by Sanderling V Biomedical Co-Investment Fund, L.P., 329,682 shares of common stock held by Sanderling Venture Partners V Co-Investment Fund, L.P. and 891,189 shares of common stock held by Sanderling V Strategic Exit Fund, L.P. (collectively, the Sanderling V Shares). The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling V Shares and the Sanderling VI Shares (as defined herein). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. The securities are held as follows: 498,046 shares of common stock held by Sanderling Venture Partners VI Co-Investment Fund, L.P., 15,431 shares of common stock held by Sanderling VI Beteiligungs GmbH & Co. KG and 18,384 shares of common stock held by Sanderling VI Limited Partnership (collectively, the Sanderling VI Shares). /s/ Michael Alrutz, Attorney-In-Fact 2023-11-20